Treatment | Page 323 of 465

Lymphoma :: Novel gallium compound offers treatment for lymphoma patients with resistant disease

Christopher Chitambar, M.D., a physician researcher at the Medical College of Wisconsin Cancer Center in Milwaukee, has identified a compound that may be effective in treating forms of non-Hodgkin’s lymphoma (a cancer of the lymphatic system) that are resistant to certain therapies. The new agent could also offer the advantages of being administered orally, rather than intravenously, making it more convenient than intravenous agents.

Cancer :: Dua Anti-reflux Valve improves quality of life for bile duct/pancreatic cancer patients

An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee. The study, using the anti-reflux biliary stent in patients with cancer of the pancreas or bile duct, has been accepted for publication in the journal Gastrointestinal Endoscopy.

Stem Cell :: Aldagen’s product to isolate cord blood stem cells

Interim data from a clinical trial using Aldagen’s product, ALDESORT? to isolate stem cells from cord blood was presented at the 48th Annual Meeting of the American Society of Hematology demonstrating improved safety and efficacy when using ALDESORT compared to the COBLT control group. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as treatment for fatal childhood cancers and genetic diseases.

Leukemia :: M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD

Researchers at the University of Texas M. D. Anderson Cancer Center reported today that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.

Cancer :: Revlimid patients live longer and remain transfusion free

Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this year’s American Society of Hematology (ASH) meeting.

Migraine :: Fear of migraine destroys quality of life for men

The unpredictability of symptoms and apprehension associated with living with migraine is limiting mens’ lives, according to research from Griffith University?s Genomics Research Centre.

Imaging :: SCAI issues recommendations to prevent kidney damage after imaging procedures

The Society for Cardiovascular Angiography and Interventions (SCAI) has released recommendations for the prevention of contrast induced nephropathy (CIN) — potentially fatal kidney damage that can occur when a special dye is injected during certain cardiovascular procedures. The consensus document, the first to be written on this topic, appears in the January 2007 issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions.

Myeloma :: Bank on a Cure researchers identify pathways mediating myeloma treatment side effects

Thalidomide is a widely prescribed treatment for multiple myeloma. However, an estimated 15 to 30 percent of patients suffer venous thromboembolisms (VTEs), blood clots, as a major complication. The Bank On A Cure DNA-bank researchers have identified four gene clusters associated with the VTEs. Identifying the associated single nucleotide polymorphisms (SNPs) for use as markers, may lead to the development of screenings and tailored interventions to prevent these side effects, as a major step toward personalized medicine.

Cancer :: AVN944 inhibits IMPDH & induces apoptosis-related biomarkers in patients with hematologic cancers

IMPDH is highly upregulated in most hematological cancers and solid tumors — an essential role in cancer cell synthesis of DNA and RNA. Inhibition of IMPDH represents a new and important approach to treat cancer. In a Phase I trial of AVN944, AvalonRx identified a set of 34 genes. These gene markers correlate with the biochemical effects of AVN944 on protein function — believed to result in tumor cell apoptosis at the right doses.

Myeloma :: Drug combination proves effective against myeloma

Two “new generation” drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial to be presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Hematology in Orlando, Fla.